请输入您要查询的百科知识：

　

词条 Allopregnanolone
释义

  1. Medical uses

  2. Side effects

  3. Biological function

  4. Mechanism of action

  5. Chemistry

     Biosynthesis  Derivatives 

  6. Society and culture

     Names 

  7. Research

  8. See also

  9. References

  10. External links

{{Drugbox
| Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
| image = Allopregnanolone.svg
| width = 225px
| alt = Skeletal formula of allopregnanolone
| image2 = Allopregnanolone-3D-balls.png
| width2 = 225px
| alt2 = Ball-and-stick model of the allopregnanolone molecule
| tradename = Zulresso
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = Rx-only
| legal_status =
| routes_of_administration = Intravenous infusion[1]
| class = Neurosteroids; Antidepressants
| bioavailability =
| protein_bound = >99%[1]
| metabolism = Non-CYP450 (keto-reduction via AKRs, glucuronidation via UGTs, sulfation via SULTs)[1]
| elimination_half-life = 9 hours[1]
| excretion = Feces: 47%[1]
Urine: 42%[1]
| CAS_number_Ref =
| CAS_number = 516-54-1
| CAS_supplemental =
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =
| PubChem = 92786
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank = DB11859
| ChemSpiderID_Ref =
| ChemSpiderID = 83760
| UNII = S39XZ5QV8Y
| KEGG = D11149
| ChEBI = 50169
| ChEMBL = 207538
| synonyms = ALLO; Allo; ALLOP; AlloP; Brexanolone; SAGE-547; SGE-102; 5α-Pregnan-3α-ol-20-one; 3α-Hydroxy-5α-pregnan-20-one; 3α,5α-Tetrahydroprogesterone; 3α,5α-THP
| C=21 | H=34 | O=2
| molecular_weight = 318.501 g/mol
| SMILES = CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
| StdInChI_Ref =
| StdInChI = 1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
| StdInChIKey_Ref =
| StdInChIKey = AURFZBICLPNKBZ-SYBPFIFISA-N
}}Allopregnanolone, also known as brexanolone, is a medication and a naturally produced steroid that acts on the brain.[1][8] As a medication it is sold under the brand name Zulresso[2] and used to treat postpartum depression.[3][4][5] It is used by injection into a vein over a 60-hour period under medical supervision.[3]

Side effects of brexanolone may include sleepiness, dry mouth, and loss of consciousness.[1][3] It is a neurosteroid and acts as a positive allosteric modulator of the GABAA receptor, the major biological target of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).[6]

Brexanolone was approved for medical use in the United States in 2019 with commercial sales expected to begin in June 2019.[7][18] The long administration time, as well as the cost of {{US$|34,000}}, have raised concerns about accessibility for many women.[8]

Medical uses

Brexanolone is used to treat postpartum depression in women.[3]

Side effects

Side effects may include sleepiness, dry mouth, and loss of consciousness.[6][3]

Biological function

Allopregnanolone possesses a wide variety of effects, including, in no particular order, antidepressant, anxiolytic, stress-reducing, rewarding,[9] prosocial,[10] antiaggressive,[11] prosexual,[10] sedative, pro-sleep,[12] cognitive, memory-impairment, analgesic,[13] anesthetic, anticonvulsant, neuroprotective, and neurogenic effects.[1] Fluctuations in the levels of allopregnanolone and the other neurosteroids seem to play an important role in the pathophysiology of mood, anxiety, premenstrual syndrome, catamenial epilepsy, and various other neuropsychiatric conditions.[14][15][16]

Increased levels of allopregnanolone can produce paradoxical effects, including negative mood, anxiety, irritability, and aggression.[17][18][19] This appears to be because allopregnanolone possesses biphasic, U-shaped actions at the GABAA receptor – moderate level increases (in the range of 1.5–2 nM/L total allopregnanolone, which are approximately equivalent to luteal phase levels) inhibit the activity of the receptor, while lower and higher concentration increases stimulate it.[17][18] This seems to be a common effect of many GABAA receptor positive allosteric modulators.[14][19] In accordance, acute administration of low doses of micronized progesterone (which reliably elevates allopregnanolone levels) has been found to have negative effects on mood, while higher doses have a neutral effect.[20]

During pregnancy, allopregnanolone and pregnanolone are involved in sedation and anesthesia of the fetus.[21][22]

Mechanism of action

It is an endogenous inhibitory pregnane neurosteroid.[23] It is made from progesterone, and is a positive allosteric modulator of the action of γ-aminobutyric acid (GABA) at GABAA receptor.[1] Allopregnanolone has effects similar to those of other positive allosteric modulators of the GABA action at GABAA receptor such as the benzodiazepines, including anxiolytic, sedative, and anticonvulsant activity.[1][24][25] Endogenously produced allopregnanolone exerts a neurophysiological role by fine-tuning of GABAA receptor and modulating the action of several positive allosteric modulators and agonists at GABAA receptor.[26]

Allopregnanolone acts as a highly potent positive allosteric modulator of the GABAA receptor.[1] While allopregnanolone, like other inhibitory neurosteroids such as THDOC, positively modulates all GABAA receptor isoforms, those isoforms containing δ subunits exhibit the greatest potentiation.[27] Allopregnanolone has also been found to act as a positive allosteric modulator of the GABAA-ρ receptor, though the implications of this action are unclear.[28][29] In addition to its actions on GABA receptors, allopregnanolone, like progesterone, is known to be a negative allosteric modulator of nACh receptors,[30] and also appears to act as a negative allosteric modulator of the 5-HT3 receptor.[31] Along with the other inhibitory neurosteroids, allopregnanolone appears to have little or no action at other ligand-gated ion channels, including the NMDA, AMPA, kainate, and glycine receptors.[32]

Unlike progesterone, allopregnanolone is inactive at the classical nuclear progesterone receptor (PR).[32] However, allopregnanolone can be intracellularly oxidized into 5α-dihydroprogesterone, which does act as an agonist of the PR, and for this reason, allopregnanolone can produce PR-mediated progestogenic effects.[33][34] In addition, allopregnanolone has recently been found to be an agonist of the newly discovered membrane progesterone receptors (mPRs), including mPRδ, mPRα, and mPRβ, with its activity at these receptors about a magnitude more potent than at the GABAA receptor.[35][36] The action of allopregnanolone at these receptors may be related, in part, to its neuroprotective and antigonadotropic properties.[35][37] Also like progesterone, recent evidence has shown that allopregnanolone is an activator of the pregnane X receptor.[32][38]

Similarly to many other GABAA receptor positive allosteric modulators, allopregnanolone has been found to act as an inhibitor of L-type voltage-gated calcium channels (L-VGCCs),[39] including α1 subtypes Cav1.2 and Cav1.3.[40] However, the threshold concentration of allopregnanolone to inhibit L-VGCCs was determined to be 3 μM (3,000 nM), which is far greater than the concentration of 5 nM that has been estimated to be naturally produced in the human brain.[40] Thus, inhibition of L-VGCCs is unlikely of any actual significance in the effects of endogenous allopregnanolone.[40] Also, allopregnanolone, along with several other neurosteroids, has been found to activate the G protein-coupled bile acid receptor (GPBAR1, or TGR5).[41] However, it is only able to do so at micromolar concentrations, which, similarly to the case of the L-VGCCs, are far greater than the low nanomolar concentrations of allopregnanolone estimated to be present in the brain.[41]

Chemistry

{{See also|List of neurosteroids}}

Allopregnanolone is a pregnane (C21) steroid and is also known as 5α-pregnan-3α-ol-20-one, 3α-hydroxy-5α-pregnan-20-one, or 3α,5α-tetrahydroprogesterone (3α,5α-THP). It is very closely related structurally to 5-pregnenolone (pregn-5-en-3β-ol-20-dione), progesterone (pregn-4-ene-3,20-dione), the isomers of pregnanedione (5-dihydroprogesterone; 5-pregnane-3,20-dione), the isomers of 4-pregnenolone (3-dihydroprogesterone; pregn-4-en-3-ol-20-one), and the isomers of pregnanediol (5-pregnane-3,20-diol). In addition, allopregnanolone is one of four isomers of pregnanolone (3,5-tetrahydroprogesterone), with the other three isomers being pregnanolone (5β-pregnan-3α-ol-20-one), isopregnanolone (5α-pregnan-3β-ol-20-one), and epipregnanolone (5β-pregnan-3β-ol-20-one).

Biosynthesis

The biosynthesis of allopregnanolone in the brain starts with the conversion of progesterone into 5α-dihydroprogesterone by 5α-reductase type I. After that, 3α-hydroxysteroid dehydrogenase converts this intermediate into allopregnanolone.[1] Allopregnanolone in the brain is produced by cortical and hippocampus pyramidal neurons and pyramidal-like neurons of the basolateral amygdala.[42]

Derivatives

A variety of synthetic derivatives and analogues of allopregnanolone with similar activity and effects exist, including alfadolone (3α,21-dihydroxy-5α-pregnane-11,20-dione), alfaxolone (3α-hydroxy-5α-pregnane-11,20-dione), ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one), hydroxydione (21-hydroxy-5β-pregnane-3,20-dione), minaxolone (11α-(dimethylamino)-2β-ethoxy-3α-hydroxy-5α-pregnan-20-one), Org 20599 (21-chloro-3α-hydroxy-2β-morpholin-4-yl-5β-pregnan-20-one), Org 21465 (2β-(2,2-dimethyl-4-morpholinyl)-3α-hydroxy-11,20-dioxo-5α-pregnan-21-yl methanesulfonate), and renanolone (3α-hydroxy-5β-pregnan-11,20-dione).

The 21-hydroxylated derivative of this compound, tetrahydrodeoxycorticosterone (THDOC), is an endogenous inhibitory neurosteroid with similar properties to those of allopregnanolone, and the 3β-methyl analogue of allopregnanolone, ganaxolone, is under development to treat epilepsy and other conditions, including post-traumatic stress disorder (PTSD).[1]

Society and culture

Names

Allopregnanolone is the name of the molecule commonly used in the literature when it is discussed as an endogenous neurosteroid, whereas brexanolone ({{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}})[43] is the name of the compound in the context of its use as a medication. Zulresso is the brand name of brexanolone as a medication.

Research

Aside from its use in postpartum depression, brexanolone is also under development as an intravenously administered medication for the treatment of super-refractory status epilepticus and essential tremor.[44]

Exogenous progesterone, such as oral progesterone, elevates allopregnanolone levels in the body with good dose-to-serum level correlations.[45] Due to this, it has been suggested that oral progesterone could be described as a prodrug of sorts for allopregnanolone.[45] As a result, there has been some interest in using oral progesterone to treat catamenial epilepsy,[46] as well as other menstrual cycle-related and neurosteroid-associated conditions. In addition to oral progesterone, oral pregnenolone has also been found to act as a prodrug of allopregnanolone,[47][48][49] though also of pregnenolone sulfate.[50]

See also

  • List of investigational antidepressants

References

1. ^1 2 3 4 5 6 {{cite book|url=|title=Neurosteroids: endogenous role in the human brain and therapeutic potentials|author=Reddy DS|journal=Prog. Brain Res.|year=2010|isbn=9780444536303|series=Progress in Brain Research|volume=186|pages=113–37|doi=10.1016/B978-0-444-53630-3.00008-7|pmc=3139029|pmid=21094889|issue=}}
2. ^{{cite web|title=ChemIDplus - 516-54-1 - AURFZBICLPNKBZ-SYBPFIFISA-N - Brexanolone [USAN] - Similar structures search, synonyms, formulas, resource links, and other chemical information.|url=https://chem.nlm.nih.gov/chemidplus/rn/516-54-1|publisher=NIH Toxnet|accessdate=26 December 2017|language=en}}
3. ^1 2 3 4 5 {{cite web |last1=Commissioner |first1=Office of the |title=Press Announcements - FDA approves first treatment for post-partum depression |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm |website=www.fda.gov |accessdate=21 March 2019 |language=en}}
4. ^{{cite journal | vauthors = Frieder A, Fersh M, Hainline R, Deligiannidis KM | title = Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development | journal = CNS Drugs | volume = 33 | issue = 3 | pages = 265–282 | date = March 2019 | pmid = 30790145 | doi = 10.1007/s40263-019-00605-7 | url = }}
5. ^{{cite journal | vauthors = Wilkinson ST, Sanacora G | title = A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems | journal = Drug Discov. Today | volume = 24 | issue = 2 | pages = 606–615 | date = February 2019 | pmid = 30447328 | doi = 10.1016/j.drudis.2018.11.007 | url = }}
6. ^1 2 3 4 5 6 7 8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf
7. ^{{cite web |last1=Commissioner |first1=Office of the |title=Press Announcements - FDA approves first treatment for post-partum depression |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm |website=www.fda.gov |accessdate=21 March 2019 |language=en}}
8. ^{{cite news |last1=Chatterjee |first1=Rhitu |title=New Postpartum Depression Drug Could Be Hard To Access For Moms Most In Need |url=https://www.npr.org/sections/health-shots/2019/03/21/705545014/new-postpartum-depression-drug-could-be-hard-to-access-for-moms-most-in-need |work=NPR |accessdate=22 March 2019 |language=en}}
9. ^{{cite journal |vauthors=Rougé-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV | title = The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens | journal = Eur. J. Neurosci. | volume = 16 | issue = 1 | pages = 169–73 |date=July 2002 | pmid = 12153544 | doi = 10.1046/j.1460-9568.2002.02084.x| url = }}
10. ^1 {{cite journal | author = Frye CA | title = Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions | journal = Psychoneuroendocrinology | volume = 34 Suppl 1 | issue = | pages = S143–61 |date=December 2009 | pmid = 19656632 | pmc = 2898141 | doi = 10.1016/j.psyneuen.2009.07.005 | url = http://linkinghub.elsevier.com/retrieve/pii/S0306-4530(09)00216-9 }}
11. ^{{cite journal |vauthors=Pinna G, Costa E, Guidotti A | title = Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 102 | issue = 6 | pages = 2135–40 |date=February 2005 | pmid = 15677716 | pmc = 548579 | doi = 10.1073/pnas.0409643102 | url = }}
12. ^{{cite journal |vauthors=Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J | title = Steroid hormones and sleep regulation | journal = Mini Rev Med Chem | volume = 12 | issue = 11 | pages = 1040–8 |date=October 2012 | pmid = 23092405 | doi = 10.2174/138955712802762167| url = http://www.eurekaselect.com/102482/article }}
13. ^{{cite journal |vauthors=Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG | title = Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain | journal = Prog. Neurobiol. | volume = 113 | issue = | pages = 70–8 |date=February 2014 | pmid = 23948490 | doi = 10.1016/j.pneurobio.2013.07.004 | url = }}
14. ^1 {{cite journal |vauthors=Bäckström T, Andersson A, Andreé L | title = Pathogenesis in menstrual cycle-linked CNS disorders | journal = Ann. N. Y. Acad. Sci. | volume = 1007 | issue = | pages = 42–53 |date=December 2003 | pmid = 14993039 | doi = 10.1196/annals.1286.005 |display-authors=etal}}
15. ^{{cite journal |vauthors=Guille C, Spencer S, Cavus I, Epperson CN | title = The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment | journal = Epilepsy Behav | volume = 13 | issue = 1 | pages = 12–24 |date=July 2008 | pmid = 18346939 | doi = 10.1016/j.yebeh.2008.02.004 | url = | pmc=4112568}}
16. ^{{cite journal |vauthors=Finocchi C, Ferrari M | title = Female reproductive steroids and neuronal excitability | journal = Neurol. Sci. | volume = 32 Suppl 1 | issue = | pages = S31–5 |date=May 2011 | pmid = 21533709 | doi = 10.1007/s10072-011-0532-5 | url = }}
17. ^1 {{cite journal |vauthors=Bäckström T, Haage D, Löfgren M | title = Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons | journal = Neuroscience | volume = 191 | issue = | pages = 46–54 |date=September 2011 | pmid = 21600269 | doi = 10.1016/j.neuroscience.2011.03.061 | url = |display-authors=etal}}
18. ^1 {{cite journal |vauthors=Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T | title = Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators | journal = Psychoneuroendocrinology | volume = 34 | issue = 8 | pages = 1121–32 |date=September 2009 | pmid = 19272715 | doi = 10.1016/j.psyneuen.2009.02.003 | url = }}
19. ^1 {{cite journal |vauthors=Bäckström T, Bixo M, Johansson M | title = Allopregnanolone and mood disorders | journal = Prog. Neurobiol. | volume = 113 | issue = | pages = 88–94 |date=February 2014 | pmid = 23978486 | doi = 10.1016/j.pneurobio.2013.07.005 | url = |display-authors=etal}}
20. ^{{cite journal |vauthors=Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T | title = Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone | journal = Psychopharmacology | volume = 187 | issue = 2 | pages = 209–21 |date=August 2006 | pmid = 16724185 | doi = 10.1007/s00213-006-0417-0 | url = }}
21. ^{{cite journal | vauthors = Mellor DJ, Diesch TJ, Gunn AJ, Bennet L | title = The importance of 'awareness' for understanding fetal pain | journal = Brain Res. Brain Res. Rev. | volume = 49 | issue = 3 | pages = 455–71 | year = 2005 | pmid = 16269314 | doi = 10.1016/j.brainresrev.2005.01.006 | url = }}
22. ^{{cite journal | vauthors = Lagercrantz H, Changeux JP | title = The emergence of human consciousness: from fetal to neonatal life | journal = Pediatr. Res. | volume = 65 | issue = 3 | pages = 255–60 | year = 2009 | pmid = 19092726 | doi = 10.1203/PDR.0b013e3181973b0d | url = https://philpapers.org/rec/LAGTEO-5| quote = [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36).}}
23. ^{{cite book|url=|title=Neurosteroids: endogenous role in the human brain and therapeutic potentials|author=Reddy DS|journal=Prog. Brain Res.|year=2010|isbn=9780444536303|series=Progress in Brain Research|volume=186|pages=113–37|doi=10.1016/B978-0-444-53630-3.00008-7|pmc=3139029|pmid=21094889|issue=}}
24. ^{{cite journal | author=Reddy DS, Rogawski MA |title= Neurosteroids — Endogenous Regulators of Seizure Susceptibility and Role in the Treatment of Epilepsy | journal= Jasper's Basic Mechanisms of the Epilepsies, 4th Edition |pages= 984–1002 | year=2012 | url=https://www.ncbi.nlm.nih.gov/books/NBK98218/|doi= 10.1093/med/9780199746545.003.0077 |isbn= 9780199746545 }}
25. ^{{Cite journal | author = T. G. Kokate, B. E. Svensson & M. A. Rogawski | title = Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 270 | issue = 3 | pages = 1223–1229 | date=September 1994 | pmid = 7932175}}
26. ^{{Cite journal|title = Brain allopregnanolone regulates the potency of the GABAA receptor agonist muscimol|url = http://www.sciencedirect.com/science/article/pii/S0028390899001495|journal = Neuropharmacology|date = 2000-03-01|pages = 440–448|volume = 39|issue = 3|doi = 10.1016/S0028-3908(99)00149-5|first = G|last = Pinna|first2 = V|last2 = Uzunova|first3 = K|last3 = Matsumoto|first4 = G|last4 = Puia|first5 = J. -M|last5 = Mienville|first6 = E|last6 = Costa|first7 = A|last7 = Guidotti|pmid=10698010}}
27. ^{{cite journal |vauthors=Mousavi Nik A, Pressly B, Singh V, Antrobus S, Hulsizer S, Rogawski MA, Wulff H, Pessah IN |title=Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye |journal=Mol. Pharmacol. |volume= 92|issue= 1|pages= 88–99|year=2017 |pmid=28428226 |doi=10.1124/mol.117.108563 |pmc=5452057}}
28. ^{{cite journal |vauthors=Morris KD, Moorefield CN, Amin J | title = Differential modulation of the gamma-aminobutyric acid type C receptor by neuroactive steroids | journal = Mol. Pharmacol. | volume = 56 | issue = 4 | pages = 752–9 |date=October 1999 | pmid = 10496958 | doi = | url = }}
29. ^{{cite journal |vauthors=Li W, Jin X, Covey DF, Steinbach JH | title = Neuroactive steroids and human recombinant rho1 GABAC receptors | journal = J. Pharmacol. Exp. Ther. | volume = 323 | issue = 1 | pages = 236–47 |date=October 2007 | pmid = 17636008 | doi = 10.1124/jpet.107.127365 | url = | pmc = 3905684 }}
30. ^{{cite journal |vauthors=Bullock AE, Clark AL, Grady SR | title = Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes | journal = J. Neurochem. | volume = 68 | issue = 6 | pages = 2412–23 |date=June 1997 | pmid = 9166735 | doi = 10.1046/j.1471-4159.1997.68062412.x |display-authors=etal}}
31. ^{{cite journal |vauthors=Wetzel CH, Hermann B, Behl C | title = Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor | journal = Mol. Endocrinol. | volume = 12 | issue = 9 | pages = 1441–51 |date=September 1998 | pmid = 9731711 | doi = 10.1210/mend.12.9.0163 | url = |display-authors=etal}}
32. ^1 2 {{cite journal | author = Mellon SH | title = Neurosteroid regulation of central nervous system development | journal = Pharmacol. Ther. | volume = 116 | issue = 1 | pages = 107–24 |date=October 2007 | pmid = 17651807 | pmc = 2386997 | doi = 10.1016/j.pharmthera.2007.04.011 | url = http://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00109-X}}
33. ^{{cite journal |vauthors=Rupprecht R, Reul JM, Trapp T | title = Progesterone receptor-mediated effects of neuroactive steroids | journal = Neuron | volume = 11 | issue = 3 | pages = 523–30 |date=September 1993 | pmid = 8398145 | doi = 10.1016/0896-6273(93)90156-l| url = |display-authors=etal}}
34. ^{{cite journal | vauthors = Reddy DS, Estes WA | title = Clinical Potential of Neurosteroids for CNS Disorders | journal = Trends Pharmacol. Sci. | volume = 37 | issue = 7 | pages = 543–561 | date = July 2016 | pmid = 27156439 | pmc = 5310676 | doi = 10.1016/j.tips.2016.04.003 | url = }}
35. ^1 {{cite journal |vauthors=Thomas P, Pang Y | title = Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells | journal = Neuroendocrinology | volume = 96 | issue = 2 | pages = 162–71 | year = 2012 | pmid = 22687885 | pmc = 3489003 | doi = 10.1159/000339822 | url = }}
36. ^{{cite journal |vauthors=Pang Y, Dong J, Thomas P | title = Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors δ and {epsilon} (mPRδ and mPR{epsilon}) and mPRδ involvement in neurosteroid inhibition of apoptosis | journal = Endocrinology | volume = 154 | issue = 1 | pages = 283–95 | date = January 2013 | pmid = 23161870 | pmc = 3529379 | doi = 10.1210/en.2012-1772 | url = }}
37. ^{{cite journal |vauthors=Sleiter N, Pang Y, Park C | title = Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release | journal = Endocrinology | volume = 150 | issue = 8 | pages = 3833–44 |date=August 2009 | pmid = 19423765 | pmc = 2717864 | doi = 10.1210/en.2008-0774 | url = |display-authors=etal}}
38. ^{{cite journal |vauthors=Lamba V, Yasuda K, Lamba JK | title = PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators | journal = Toxicol. Appl. Pharmacol. | volume = 199 | issue = 3 | pages = 251–65 |date=September 2004 | pmid = 15364541 | doi = 10.1016/j.taap.2003.12.027 | url = |display-authors=etal}}
39. ^{{cite journal |vauthors=Hu AQ, Wang ZM, Lan DM | title = Inhibition of evoked glutamate release by neurosteroid allopregnanolone via inhibition of L-type calcium channels in rat medial prefrontal cortex | journal = Neuropsychopharmacology | volume = 32 | issue = 7 | pages = 1477–89 |date=July 2007 | pmid = 17151597 | doi = 10.1038/sj.npp.1301261 | url = |display-authors=etal}}
40. ^1 2 {{cite journal |vauthors=Earl DE, Tietz EI | title = Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors | journal = J. Pharmacol. Exp. Ther. | volume = 337 | issue = 1 | pages = 301–11 |date=April 2011 | pmid = 21262851 | pmc = 3063747 | doi = 10.1124/jpet.110.178244 | url = }}
41. ^1 {{cite journal |vauthors=Keitel V, Görg B, Bidmon HJ | title = The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain | journal = Glia | volume = 58 | issue = 15 | pages = 1794–805 |date=November 2010 | pmid = 20665558 | doi = 10.1002/glia.21049 | url = |display-authors=etal}}
42. ^{{Cite journal|title = Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis|url = http://www.pnas.org/content/103/39/14602|journal = Proceedings of the National Academy of Sciences|date = 2006-09-26|issn = 0027-8424|pmc = 1600006|pmid = 16984997|pages = 14602–14607|volume = 103|issue = 39|doi = 10.1073/pnas.0606544103|language = en|first = Roberto C.|last = Agís-Balboa|first2 = Graziano|last2 = Pinna|first3 = Adrian|last3 = Zhubi|first4 = Ekrem|last4 = Maloku|first5 = Marin|last5 = Veldic|first6 = Erminio|last6 = Costa|first7 = Alessandro|last7 = Guidotti}}
43. ^https://www.genome.jp/dbget-bin/www_bget?dr:D11149
44. ^1 {{cite web|title=Brexanolone - Sage Therapeutics|url=http://adisinsight.springer.com/drugs/800039944|publisher=AdisInsight|language=en}}
45. ^1 {{cite journal |vauthors=Andréen L, Spigset O, Andersson A, Nyberg S, Bäckström T | title = Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone | journal = Maturitas | volume = 54 | issue = 3 | pages = 238–44 |date=June 2006 | pmid = 16406399 | doi = 10.1016/j.maturitas.2005.11.005 | url = }}
46. ^{{cite book | author1 = Orrin Devinsky | author2 = Steven Schachter | author3 = Steven Pacia | title = Complementary and Alternative Therapies for Epilepsy | url = https://books.google.com/books?id=WVUE-6Xdny4C&pg=PT378 | date = 1 January 2005 | publisher = Demos Medical Publishing | isbn = 978-1-934559-08-6 | pages = 378–}}
47. ^{{cite journal | vauthors = Saudan C, Desmarchelier A, Sottas PE, Mangin P, Saugy M | title = Urinary marker of oral pregnenolone administration | journal = Steroids | volume = 70 | issue = 3 | pages = 179–83 | year = 2005 | pmid = 15763596 | doi = 10.1016/j.steroids.2004.12.007 | url = }}
48. ^{{cite journal | vauthors = Piper T, Schlug C, Mareck U, Schänzer W | title = Investigations on changes in ¹³C/¹²C ratios of endogenous urinary steroids after pregnenolone administration | journal = Drug Test Anal | volume = 3 | issue = 5 | pages = 283–90 | year = 2011 | pmid = 21538944 | doi = 10.1002/dta.281 | url = }}
49. ^{{cite journal | vauthors = Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, Liberzon I | title = Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits | journal = Biol. Psychiatry | volume = 73 | issue = 11 | pages = 1045–53 | year = 2013 | pmid = 23348009 | pmc = 3648625 | doi = 10.1016/j.biopsych.2012.12.008 | url = }}
50. ^{{cite journal | vauthors = Ducharme N, Banks WA, Morley JE, Robinson SM, Niehoff ML, Mattern C, Farr SA | title = Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration | journal = Eur. J. Pharmacol. | volume = 641 | issue = 2–3 | pages = 128–34 | year = 2010 | pmid = 20570588 | pmc = 3008321 | doi = 10.1016/j.ejphar.2010.05.033 | url = }}

External links

  • [https://druginfo.nlm.nih.gov/drugportal/rn/516-54-1 Health information from the NIH]
  • [https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf Zulresso (brexanolone) FDA label]
  • [https://adisinsight.springer.com/drugs/800039944 Brexanolone - AdisInsight]
  • {{cite journal | last1=Herd | first1=MB | last2= Belelli |first2=D |last3=Lambert |first3=JJ |title= Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors | journal=Pharmacology & Therapeutics | volume=116 | issue=1 | pages=20–34 |url= http://www.journals.elsevier.com/pharmacology-and-therapeutics|format= |accessdate= |edition= |year= 2007 |language= |id= |doi= 10.1016/j.pharmthera.2007.03.007 | pmid=17531325 }}
{{Progesterone}}{{Endogenous steroids}}{{Navboxes
| title = Biological activity
| titlestyle = background:#ccccff
| list1 ={{GABAA receptor positive allosteric modulators}}{{Glycine receptor modulators}}{{Nicotinic acetylcholine receptor modulators}}{{Progesterone receptor modulators}}{{Xenobiotic-sensing receptor modulators}}
}}

12 : Anticonvulsants|Antidepressants|Neurosteroids|Alcohols|Ketones|GABAA receptor positive allosteric modulators|GABAA-rho receptor positive allosteric modulators|Glycine receptor agonists|Nicotinic antagonists|Progestogens|Pregnane X receptor agonists|Pregnanes
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/22 3:30:16